Physician

Akinfemi Samson Afolabi, M.D.

According to 2025 Medicare claims, Akinfemi Afolabi, M.D. (NPI: 1992782965) practices nephrology in the Toledo, OH market, with the plurality of this provider's patient population coming from Lucas, OH. This provider's primary affiliated billing organization is RENAL SERVICES OF TOLEDO, INC (NPI: 1225015605; TIN: 341970904) and primary practice location at 43616-3207. Afolabi is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Afolabi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 379 traditional Medicare patients, billed 1,572 HCPCS/CPT codes, and received $144,326 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,256 prescription claims across 269 beneficiaries totaling $111,828 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). 2018 DME data shows 41 claims. Open Payments data shows 2 records totaling $34. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $454,899 to $111,828. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	463	1,817	$182,070
2016	470	1,941	$175,196
2017	485	1,705	$157,450
2018	497	2,075	$196,196
2019	485	1,934	$177,737
2020	393	1,515	$153,830
2021	360	1,381	$153,845
2022	325	1,306	$141,106
2023	348	1,346	$129,071
2024	379	1,572	$144,326

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	243	2,460	$454,899
2016	227	2,304	$455,495
2017	222	1,917	$302,492
2018	217	1,793	$138,683
2019	195	1,389	$126,112
2020	183	1,128	$122,883
2021	184	944	$97,817
2022	169	927	$102,200
2023	199	1,024	$89,431
2024	269	1,256	$111,828

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$263
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	41	$602
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	103	107	$128
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	69	88	$98
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	63	85	$80
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	108	159	$61
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	199	848	$55

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	20	1,215	$25,516
Farxiga	Dapagliflozin Propanediol	18	1,293	$24,458
Sevelamer Carbonate	Sevelamer Carbonate	76	2,870	$18,917
Calcium Acetate	Calcium Acetate	59	2,417	$4,493
Bumetanide	Bumetanide	48	2,647	$2,062

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$34	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Akinfemi Samson Afolabi, M.D.?

Tedicare shows public-source Medicare data for Akinfemi Samson Afolabi, M.D. (NPI 1992782965), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Akinfemi Samson Afolabi, M.D. have ACO affiliation data?

Akinfemi Samson Afolabi, M.D. is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Akinfemi Samson Afolabi, M.D.?

Akinfemi Samson Afolabi, M.D. is linked to RENAL SERVICES OF TOLEDO, INC (billing NPI 1225015605) in the available physician profile data.

Does Akinfemi Samson Afolabi, M.D. have Open Payments data?

Akinfemi Samson Afolabi, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.